11:11:49 EDT Sun 01 Aug 2021
Enter Symbol
or Name

Login ID:

Z:MRK - MERCK & CO INC - http://www.merck.com11:11:49 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRK - Z0.376.88·76.981.576.87-0.06-0.113,003.81,002,47376,31677.12  77.76  76.7783.7819  68.43319:59:01Jul 2915 min RT 2¢

Recent Trades - Last 10 of 76316
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-07-29 12:30U:MRKNews ReleaseMerck Announces Appointment of Cristal N. Downing as Chief Communications & Public Affairs Officer
2021-07-29 06:30U:MRKNews ReleaseMerck Announces Second-Quarter 2021 Financial Results
2021-07-27 13:34U:MRKNews ReleaseMerck Announces Fourth-Quarter 2021 Dividend
2021-07-27 06:45U:MRKNews ReleaseMerck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS =10)
2021-07-27 06:30U:MRKNews ReleaseFDA Approves KEYTRUDA ® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery
2021-07-22 06:45U:MRKNews ReleaseFDA Approves KEYTRUDA ® (pembrolizumab) Plus LENVIMA ® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
2021-07-21 07:14U:MRKNews ReleaseVERQUVO ® (vericiguat) Approved in the European Union
2021-07-20 06:00U:MRKNews ReleaseMerck Presents New Data from Ongoing Phase 2a Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Investigational, Once-Monthly, Oral Islatravir for HIV-1 Prevention at IAS 2021
2021-07-16 17:15U:MRKNews ReleaseMerck Announces U.S. FDA Approval of VAXNEUVANCE ™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes
2021-07-15 13:30U:MRKNews ReleaseKEYTRUDA ® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Showed Statistically Significant Event-Free Survival (EFS) Result Versus Neoadjuvant Chemotherapy Alone in High-Risk Early-Stage TNBC
2021-07-12 06:55U:MRKNews ReleaseMerck Announces Presentation of New Data from Broad HIV Program at IAS 2021
2021-07-12 06:45U:MRKNews ReleaseInterim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)
2021-07-06 06:45U:MRKNews ReleaseFDA Approves Expanded Indication for Merck ’s KEYTRUDA ® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC)